Meeting
2019 ASCO Annual Meeting
Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (Febrile) neutropenia and expanded access based on budget neutral basis.
Authors
Weijia Wang
Sandoz Inc., Princeton, NJ
Weijia Wang , Sanjeev Balu , Kim Campbell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6645)
DOI
10.1200/JCO.2019.37.15_suppl.6645
Abstract #
6645
Poster Bd #
446
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2019 ASCO Quality Care Symposium
A budget impact model for biosimilar myeloid growth factors (MGFs) within the Oncology Care Model (OCM): An oncology group practice perspective.
First Author: Ali McBride
Poster
2024 ASCO Annual Meeting
Medicare reimbursement trends of biological reference agents and their biosimilars.
First Author: John Albaugh
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) for patients with genitourinary malignancies receiving chemotherapy during the COVID-19 pandemic and implications for the future.
First Author: Nely Mercy Diaz Mejia